Company

Novo Nordisk

Semaglutide franchise, CagriSema in Phase 3. Dominant GLP-1 obesity player.

54 signals

Next earnings: 6 August 2026

Market access

Drug	Indication	Brazil	China	Mexico	UAE
Victoza liraglutide	T2D
Saxenda liraglutide	obesity	-	-	-	-
Ozempic semaglutide	T2D
Rybelsus semaglutide	T2D			-	-
Wegovy semaglutide	obesity		-	-	-

View full market access tracker

Disease Area

Source

54 of 54 signals

ClinicalTrials17 Apr 2026·Phase 3● 8/10iHigh impactPick of the week

The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis

Phase 3 trial evaluates semaglutide versus placebo in adults with non-cirrhotic NASH, measuring steatohepatitis resolution, fibrosis improvement, and cirrhosis-free survival over approximately 5 years. The study enrolled 1,205 adults and is active but not recruiting, with completion expected in 2029. This represents Novo Nordisk's push into NASH, a major unmet need with no approved GLP-1 therapies despite strong preclinical rationale. The trial's dual primary endpoints and 5-year duration suggest preparation for a pivotal regulatory filing in this large addressable market.

GLP-1Liver/NASHNovo Nordisk

PubMed17 Apr 2026·Diabetes, obesity & metabolism● 6/10i

Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials.

Semaglutide demonstrated enhanced HbA1c and weight reduction in adults with type 2 diabetes aged ≤40 years compared to older age groups across the SUSTAIN and PIONEER programs. Post hoc analysis of pooled phase 3 trials comparing subcutaneous and oral semaglutide against placebo and active comparators across age subgroups. This provides the first dedicated efficacy analysis of GLP-1 therapy in young adults with type 2 diabetes, supporting earlier intervention strategies. Safety profiles remained comparable across all age groups.

GLP-1Type 2 diabetesNovo Nordisk

PubMed17 Apr 2026·Diabetes, obesity & metabolism● 7/10i

Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study.

GLP-1 receptor agonists reduced Parkinson's disease risk by 19% versus sulfonylureas in adults with type 2 diabetes, with incidence rates of 5.2 versus 8.0 per 10,000 person-years. Scandinavian cohort study of 347,026 new users across three countries, with liraglutide accounting for 73% of GLP-1 exposure followed by semaglutide at 13%. This provides the first large-scale evidence for neuroprotective effects beyond weight loss and glycemic control in the GLP-1 class. The observational design cannot establish causation, requiring validation in randomized trials.

GLP-1Brain/NeuroType 2 diabetesNovo Nordisk Eli Lilly

PubMed17 Apr 2026·Annals of internal medicine● 7/10i

Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review.

Incretin-based therapies caused muscle-related losses that exceeded expected benchmarks in two-thirds of studies, with a median 34.9% of total weight loss coming from muscle-based tissue rather than the expected 25% threshold. Systematic review of 36 randomized controlled trials with median 71 participants and 26-week duration across liraglutide, semaglutide, tirzepatide, and dulaglutide. This quantifies a clinically important side effect profile that has received limited systematic evaluation despite widespread prescribing of these agents for weight management. The analysis was limited by heterogeneous measurement methods that prevented meta-analysis.

Weight lossGLP-1Side effectsNovo Nordisk Eli Lilly

ClinicalTrials16 Apr 2026·Phase 3● 7/10i

A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) Cirrhosis

Boehringer Ingelheim is testing survodutide, a once-weekly injectable, in people with compensated NASH/MASH cirrhosis in a phase 3 trial targeting liver-related clinical outcomes. The randomized, placebo-controlled study aims to enroll 1,590 participants over 4.5 years, measuring time to death, liver transplant, hepatic decompensation, or disease progression. This represents Boehringer's entry into the competitive NASH space where Novo Nordisk's semaglutide is already in phase 3 trials for non-cirrhotic NASH. The trial focuses on advanced cirrhotic patients, a population with high unmet need but challenging regulatory pathway.

Liver/NASHGLP-1Boehringer Ingelheim Novo Nordisk

ClinicalTrials16 Apr 2026·Phase 3● 8/10iHigh impact

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Phase 3 master protocol testing oral orforglipron versus placebo in adults with obesity or overweight, with or without type 2 diabetes. Enrolling 1,200 participants across two sub-studies, expected completion August 2027, placebo-controlled design. Eli Lilly advances orforglipron into obesity treatment following its April 2026 FDA approval for type 2 diabetes, representing the first small-molecule oral GLP-1 to enter weight management. This positions Eli Lilly to challenge Novo Nordisk's dominance in oral GLP-1 obesity treatment, where oral semaglutide gained approval in January 2026.

GLP-1Weight lossType 2 diabetesEli Lilly Novo Nordisk

PubMed16 Apr 2026·Diabetes, obesity & metabolism● 7/10i

Cardiometabolic Profiles of Oral and Subcutaneous Glucagon-Like Peptide-1 Receptor Mono-Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta-Analysis.

Semaglutide 7.2 mg achieved the highest cardiometabolic efficacy index (0.86), followed by orforglipron 36 mg (0.68) and semaglutide 2.4 mg (0.66), all producing placebo-adjusted weight reductions ≥10%. Network meta-analysis of 19 RCTs with 13,117 adults with overweight or obesity, evaluating composite outcomes across seven cardiometabolic parameters. This provides the first head-to-head comparison of oral orforglipron against both approved and investigational semaglutide doses across multiple cardiometabolic endpoints, with orforglipron showing competitive performance despite being the first small-molecule oral GLP-1.

GLP-1Weight lossDrug comparisonsEli Lilly Novo Nordisk

PubMed14 Apr 2026·Circulation● 7/10iPick of the week

Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation.

GLP-1 receptor agonists reduced heart failure hospitalization risk by 23% versus DPP-4 inhibitors (HR 0.77) but matched SGLT-2 inhibitors (HR 1.02) in adults with type 2 diabetes. Target trial emulation of Swedish health records, 63,083 patients across two comparisons, 3-year follow-up. This provides the first direct head-to-head comparison of GLP-1RAs versus SGLT-2 inhibitors for heart failure prevention, confirming cardiovascular benefits extend beyond major adverse events to heart failure hospitalization.

GLP-1SGLT2Type 2 diabetesCardiovascularReal-world evidenceNovo Nordisk Eli Lilly

PubMed14 Apr 2026·Diabetes, obesity & metabolism● 4/10i

OGT Ameliorates Diabetes-Associated Cognitive Decline via Modulation of DRP1 Function and Mitochondrial Homeostasis.

OGT deficiency disrupts mitochondrial function and drives diabetes-associated cognitive decline, while semaglutide treatment for 16 weeks reversed cognitive impairment through OGT/DRP1 pathway modulation in diabetic mouse models. Preclinical study using db/db and STZ-treated mice with behavioral assessments and hippocampal gene overexpression. This provides the first mechanistic link between OGT-mediated mitochondrial homeostasis and diabetes-related brain complications, supporting a potential neuroprotective indication for GLP-1 receptor agonists.

GLP-1Type 2 diabetesBrain/NeuroMechanismsNovo Nordisk

PubMed14 Apr 2026·Annals of internal medicine● 5/10i

Endocrinology: What You May Have Missed in 2025.

A review of 9 key endocrinology studies from 2025 examined treatment intensification strategies, emerging side effects of GLP-1 receptor agonists, and comparative safety data across diabetes and obesity therapies. Narrative review synthesizing published research from multiple clinical trials and observational studies. The compilation provides the first comprehensive assessment of GLP-1RA side effect concerns including nonarteritic anterior ischemic optic neuropathy alongside head-to-head comparisons of dulaglutide dose escalation versus tirzepatide switching. Limited by being a narrative review rather than systematic analysis of primary endpoints.

GLP-1SGLT2Type 2 diabetesSide effectsDrug comparisonsEli Lilly Novo Nordisk

PubMed14 Apr 2026·Current obesity reports● 6/10i

Prevalence and Predictors of Guideline Concordant Pediatric Obesity Care: A Narrative Review.

Pharmacotherapy use remains below 2% among eligible adolescents with obesity despite 2023 American Academy of Pediatrics guidelines recommending intensive treatment including medications. Narrative review examining adoption of 13 Key Action Statements from the AAP Clinical Practice Guideline across screening, diagnosis, and treatment domains. This reveals a massive treatment gap in pediatric obesity pharmacotherapy, where established medications like semaglutide and liraglutide have pediatric approvals but face systemic barriers to implementation. Provider hesitancy, resource limitations, and insurance coverage gaps drive the underutilization.

Weight lossReal-world evidenceNovo Nordisk

PubMed14 Apr 2026·Cell metabolism● 6/10i

The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors.

Semaglutide improved liver fibrosis, steatosis, and inflammation in mice with MASH through weight-loss-independent mechanisms targeting GLP-1 receptors on liver sinusoidal endothelial cells. Preclinical study using genetically modified mouse models with targeted GLP-1 receptor deletions and transcriptomic profiling. This identifies a novel hepatic mechanism for GLP-1 receptor agonists that could support liver indication development beyond weight loss effects. Study limited to mouse models without human validation.

GLP-1Liver/NASHMechanismsNovo Nordisk

PubMed13 Apr 2026·Diabetes, obesity & metabolism● 6/10i

Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population-Based Cohort Study.

Semaglutide showed no association with reduced risk of liver cirrhosis (HR 1.3, 95% CI 0.98-1.77) or hepatocellular carcinoma (HR 0.6, 95% CI 0.21-1.51) in adults with type 2 diabetes. Retrospective cohort study of 71,612 patients with median follow-up exceeding 4,000 days. This contradicts emerging hypotheses about GLP-1 receptor agonists providing liver protection beyond metabolic benefits, suggesting hepatic outcomes may not become a differentiated messaging opportunity.

GLP-1Type 2 diabetesLiver/NASHNovo Nordisk

ClinicalTrials13 Apr 2026·Phase 3● 8/10iHigh impact

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial

Phase 3 trial evaluating retatrutide once weekly in adults with type 2 diabetes who have obesity or overweight, including a subset with obstructive sleep apnea. Enrolling 1,000 participants across 89 weeks with completion expected May 2026, measuring weight reduction and sleep apnea improvement versus placebo. Eli Lilly advances retatrutide into dual indication territory, competing directly with Novo Nordisk's semaglutide and their own tirzepatide in the expanding cardiometabolic space. The inclusion of sleep apnea patients follows Zepbound's December 2024 OSA approval, positioning retatrutide for multiple obesity comorbidities.

GLP-1Weight lossType 2 diabetesEli Lilly Novo Nordisk

ClinicalTrials13 Apr 2026·Phase 3● 7/10i

A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Phase 3 open-label trial comparing retatrutide with semaglutide in adults with type 2 diabetes inadequately controlled on metformin with or without SGLT2 inhibitor. The study enrolls 1,250 participants over 26 months, targeting HbA1c reduction as the primary endpoint, with completion expected August 2026. Eli Lilly positions retatrutide as a direct competitor to semaglutide in the core type 2 diabetes market, testing their triple-receptor agonist against the current GLP-1 standard. The head-to-head design provides comparative evidence needed for formulary positioning and prescriber confidence.

GLP-1Type 2 diabetesDrug comparisonsEli Lilly Novo Nordisk

PubMed13 Apr 2026·Diabetes care● 6/10i

Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis.

GLP-1 receptor agonists showed the lowest risk of hepatic decompensation versus all other diabetes drug classes (HRs 0.16-0.91), while thiazolidinediones had the lowest hepatocellular carcinoma risk and SGLT2 inhibitors the lowest cirrhosis risk. Network meta-analysis of 46 observational studies including 7.1 million adults with type 2 diabetes. This provides the first comprehensive liver safety ranking across all major diabetes drug classes, potentially informing prescribing in patients with existing liver disease risk. All evidence is observational, limiting causal conclusions.

GLP-1SGLT2Type 2 diabetesLiver/NASHDrug comparisonsNovo Nordisk Eli Lilly

PubMed13 Apr 2026·The lancet. Gastroenterology & hepatology● 6/10i

Global burden of metabolic dysfunction-associated steatotic liver disease, 1990-2023, and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2023.

MASLD prevalence reached 1.3 billion people globally in 2023 (16.1% of population), with cases projected to rise 42% to 1.8 billion by 2050. Global Burden of Disease systematic analysis covering 204 countries from 1990-2023 with forecasting to 2050. This provides the first comprehensive global epidemiological baseline for MASLD, quantifying the massive addressable patient population for emerging therapies like survodutide and semaglutide. High fasting glucose emerged as the largest modifiable risk factor, followed by high BMI.

Liver/NASHGLP-1Boehringer Ingelheim Novo Nordisk

ClinicalTrials8 Apr 2026·Phase 3● 8/10iHigh impact

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. Once Weekly Versus Tirzepatide 15 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor

Phase 3 head-to-head trial compares CagriSema (dual cagrilintide and semaglutide) 2.4/2.4 mg against tirzepatide 15 mg weekly in adults with type 2 diabetes inadequately controlled on metformin with or without SGLT2 inhibitors. The randomized trial enrolled 1,000 participants with primary endpoints of HbA1c and weight change, completing in March 2026. This represents Novo Nordisk's direct challenge to Eli Lilly's tirzepatide dominance with a novel dual-agonist combination targeting both GLP-1 and amylin receptors. The head-to-head design positions CagriSema for potential differentiation in the competitive dual-agonist space.

GLP-1Type 2 diabetesDrug comparisonsNovo Nordisk Eli Lilly

ClinicalTrials8 Apr 2026·Phase 3● 8/10iHigh impact

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. Once Weekly Versus Tirzepatide 5 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2 Inhibitor or Both

Phase 3 trial compares CagriSema (cagrilintide + semaglutide combination) 1.0 mg weekly versus tirzepatide 5 mg weekly in 1,023 adults with type 2 diabetes inadequately controlled on metformin, SGLT2 inhibitor, or both. Active comparator design with 68-week duration, completion expected June 2026. This represents Novo Nordisk's direct challenge to Eli Lilly's tirzepatide dominance, testing whether dual amylin/GLP-1 combination can match dual GIP/GLP-1 efficacy in the core type 2 diabetes market. Head-to-head positioning against tirzepatide's lowest approved dose could support differentiated commercial messaging if CagriSema demonstrates superiority.

GLP-1Type 2 diabetesDrug comparisonsNovo Nordisk Eli Lilly

PubMed7 Apr 2026·Diabetes, obesity & metabolism● 6/10i

Real-World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido-TZP Study.

Tirzepatide reduced HbA1c by 1.07% and body weight by 3.1 kg over 6 months in adults with type 2 diabetes in Japanese real-world practice. Multicenter retrospective observational study of 828 patients treated for 6+ months across 10 centers in Hokkaido. The efficacy remained consistent even in patients switching from existing incretin-based medications, providing first real-world evidence of tirzepatide's effectiveness after GLP-1 failure. Discontinuation rate was 5.4% due to adverse events or other clinical reasons.

GLP-1Type 2 diabetesReal-world evidenceEli Lilly Novo Nordisk

PubMed5 Apr 2026·Obesity (Silver Spring, Md.)● 7/10i

Weight Loss With GLP-1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta-Analysis.

Tirzepatide provides greater weight loss than semaglutide or liraglutide in adults with obesity without diabetes, with maximum tolerated doses achieving the largest reductions followed by tirzepatide 15mg, 10mg, semaglutide 2.4mg, tirzepatide 5mg, and liraglutide 3mg. Network meta-analysis of 15 RCTs, 14,059 patients. This is the first head-to-head comparison across all three FDA-approved obesity medications in adults without diabetes, establishing tirzepatide's superiority over existing GLP-1 options.

GLP-1Weight lossDrug comparisonsEli Lilly Novo Nordisk

PubMed2 Apr 2026·The New England journal of medicine● 6/10i

GLP-1 Receptor Agonists.

GLP-1 receptor agonists reduce cardiovascular risk and slow renal failure progression in high-risk patients with type 2 diabetes through large-scale randomized controlled trials. Review article in NEJM summarizing established mechanisms and clinical benefits. Confirms cardiovascular and kidney benefits already incorporated into current prescribing guidelines and reimbursement decisions. Highlights ongoing concerns about muscle and bone mass loss as potential long-term safety considerations.

GLP-1Type 2 diabetesWeight lossCardiovascularKidneySide effectsNovo Nordisk Eli Lilly

PubMed1 Apr 2026·Obesity science & practice● 5/10i

Targeting Multiple Gut-Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy.

Gut hormone analogs (GLP-1s like semaglutide, tirzepatide) and naltrexone-bupropion combination target different brain pathways in obesity treatment, creating mechanistic rationale for combination therapy. Narrative review synthesizing existing evidence on gut-brain axis mechanisms. This establishes the scientific foundation for combining GLP-1 receptor agonists with naltrexone-bupropion in patients with inadequate response to monotherapy.

GLP-1Weight lossMechanismsNovo Nordisk Eli Lilly

PubMed1 Apr 2026·Diabetes, obesity & metabolism● 6/10i

Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis.

Liraglutide improved menstrual frequency by 1.76 effect size, reduced BMI, and enhanced insulin sensitivity in women with PCOS and overweight. Meta-analysis of 7 RCTs with 330 patients showed benefits across metabolic and reproductive parameters versus control treatments. This provides first pooled evidence for GLP-1 agonist efficacy in PCOS reproductive outcomes, expanding beyond established metabolic benefits. Small sample size and high heterogeneity for menstrual frequency limit generalizability.

GLP-1Weight lossNovo Nordisk

PubMed1 Apr 2026·Obesity (Silver Spring, Md.)● 7/10i

Disparities in Prescription of Long-Acting GLP-1s.

Black and Hispanic patients with obesity were 49% and 47% less likely to receive semaglutide or tirzepatide compared to White patients, disparities that largely disappeared after Massachusetts Medicaid expanded coverage. Retrospective analysis of 2,060 patients at a tertiary care center, January and April 2024. This provides the first evidence that state Medicaid coverage policy directly eliminates racial prescribing disparities for GLP-1 medications. Analysis limited to single health system in Massachusetts.

GLP-1Pricing/accessNovo Nordisk Eli Lilly

PubMed1 Apr 2026·Diabetes, obesity & metabolism● 6/10i

A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial.

About 23-34% of patients with obesity treated with tirzepatide and 14-21% treated with semaglutide reached proposed treat-to-target thresholds for waist-to-height ratio or BMI reduction. Post hoc analysis of SURMOUNT-5 trial, 751 patients, 72 weeks. This provides the first structured target framework for obesity treatment goals, moving beyond simple weight loss percentages to defined metabolic risk thresholds. The analysis was post hoc rather than a prespecified endpoint.

GLP-1Weight lossDrug comparisonsEli Lilly Novo Nordisk

PubMed1 Apr 2026·Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery● 7/10i

Cardiovascular outcomes and mortality of bariatric surgery versus glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis.

Bariatric surgery reduced mortality by 43%, major cardiovascular events by 35%, and heart failure by 55% compared to GLP-1 receptor agonists in adults with obesity. Meta-analysis of 5 observational cohorts, 39,569 patients. This provides the first head-to-head comparison of these major obesity treatments on hard cardiovascular outcomes, showing substantial advantages for surgery. Observational design limits causal inference due to potential confounding and selection bias.

GLP-1CardiovascularWeight lossNovo Nordisk Eli Lilly

PubMed1 Apr 2026·International journal of obesity (2005)● 6/10i

Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.

Tirzepatide achieved 31.6% weight reduction versus 19.7% for semaglutide and 24.1% for retatrutide in MC4R knockout mice, a model of severe genetic obesity. Preclinical study, 21-day treatment duration in mice deficient in melanocortin pathways. This provides the first head-to-head comparison of major GLP-1 therapies in severe genetic obesity, suggesting these agents work through MC4R-independent mechanisms.

GLP-1Weight lossDrug comparisonsEli Lilly Novo Nordisk

PubMed1 Apr 2026·Diabetes, obesity & metabolism● 6/10i

GLP-1 receptor agonists and cardiovascular outcomes in Asian, Black or African American, and White populations: An updated meta-analysis including the SOUL trial.

GLP-1 receptor agonists reduced cardiovascular risk by 27% in Asian populations versus 14% in White populations, with similar but non-significant effects in Black or African American populations. Meta-analysis of 9 trials including 74,703 participants with type 2 diabetes or overweight/obesity. This provides the first robust evidence of differential GLP-1RA cardiovascular benefits across racial groups, with Asian populations showing significantly greater relative risk reduction. The finding emerges from inclusion of the recent SOUL trial data.

GLP-1CardiovascularNovo Nordisk Eli Lilly

PubMed1 Apr 2026·Heart, lung & circulation● 7/10i

Initiators of Semaglutide in General Practice in New South Wales, 2020-2023: A Retrospective Cohort Study.

Semaglutide initiations in New South Wales increased 82-fold from 448 in 2020 to 36,814 in 2023, with the proportion prescribed for people without type 2 diabetes rising from 8% to 34%. Retrospective cohort analysis of 59,009 patients across 680 general practices, 2020-2023. This provides first real-world evidence of semaglutide's rapid expansion into weight management, confirming the market shift toward non-diabetes indications that Novo Nordisk has actively pursued. The study reveals socioeconomic disparities in access that could influence reimbursement discussions.

GLP-1Weight lossType 2 diabetesPricing/accessReal-world evidenceNovo Nordisk

PubMed1 Apr 2026·Diabetes, obesity & metabolism● 5/10i

Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial.

Lixisenatide showed no effect on aortic pulse wave velocity, a cardiovascular risk marker, in adults with type 2 diabetes and chronic kidney disease after 24 weeks versus placebo. Randomized controlled trial of 90 patients, 24 weeks, double-blind design with placebo control. This provides mechanistic insight into why short-acting GLP-1 receptor agonists like lixisenatide showed neutral cardiovascular outcomes in trials while longer-acting agents demonstrated benefits. The study was limited to a single center with modest sample size.

GLP-1CardiovascularKidneyType 2 diabetesSanofi Novo Nordisk Eli Lilly

FDA1 Apr 2026·New Drug Approval (NDA/BLA)● 10/10iHigh impact

FDA Approves Foundayo (Orforglipron) — New Drug Approval (NDA/BLA)

FDA approved orforglipron (Foundayo, Eli Lilly) for type 2 diabetes -- a once-daily oral small-molecule GLP-1 receptor agonist. Orforglipron is the first non-peptide oral GLP-1 approved in the US; oral semaglutide (Rybelsus, Novo Nordisk) has been approved for T2D since 2019 and expanded to obesity in January 2026. Unlike Rybelsus, orforglipron requires no fasting or water volume restrictions before dosing.

GLP-1Type 2 diabetesPricing/accessEli Lilly Novo Nordisk

PubMed31 Mar 2026·Journal of the American College of Cardiology● 6/10i

Obesity and Heart Failure With Reduced Ejection Fraction: A Review.

Most patients with heart failure with reduced ejection fraction have overweight or obesity, but weight loss interventions remain unexplored in this population despite proven safety and efficacy in heart failure with preserved ejection fraction. This JACC review synthesizes existing evidence across multiple studies. The analysis reveals a critical research gap as no novel obesity pharmacotherapies are currently being evaluated specifically in patients with HFrEF, despite mechanistic rationale suggesting potential benefit.

GLP-1Weight lossCardiovascularNovo Nordisk Eli Lilly

PubMed30 Mar 2026·BMJ open diabetes research & care● 6/10i

Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH.

Switching from dulaglutide to tirzepatide provided superior HbA1c reduction (greater in high baseline HbA1c, low BMI) and weight loss (greater in non-Hispanic populations) across all patient subgroups at 40 weeks. Phase IV RCT, open-label, active-controlled, adults with type 2 diabetes on stable dulaglutide for 6+ months. This is the first head-to-head switching study between GLP-1 agents, establishing tirzepatide's superiority over Novo's dulaglutide across diverse patient populations.

GLP-1Type 2 diabetesDrug comparisonsEli Lilly Novo Nordisk

ClinicalTrials30 Mar 2026·Phase 3● 8/10iHigh impact

Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity

Phase 3 trial testing CagriSema (cagrilintide + semaglutide 2.4mg combination) versus placebo, cagrilintide alone, and semaglutide alone in 3,400 people with overweight or obesity. The 1.5-year main study plus 2-year extension tracks weight loss and maintenance after stopping treatment. Novo Nordisk is advancing its dual-hormone combination therapy against established GLP-1 monotherapy to potentially expand its obesity franchise beyond Wegovy. The extension phase design addresses a key clinical question about weight regain after discontinuation that could influence prescriber confidence and payer coverage decisions.

GLP-1Weight lossNovo Nordisk

PubMed28 Mar 2026·JAMA cardiology● 8/10iHigh impact

Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.

Tirzepatide reduced a 6-component cardiorenal composite endpoint by 16% versus dulaglutide (23.7% vs 27.4%, HR 0.84) in people with type 2 diabetes and cardiovascular disease. Post hoc analysis of SURPASS-CVOT double-blind RCT, 13,165 patients, median 46.9 months follow-up. This provides the first head-to-head cardiorenal comparison between tirzepatide and a GLP-1 agonist in high-risk cardiovascular patients, extending beyond the primary non-inferiority finding. Gastrointestinal adverse events were higher with tirzepatide (42.5% vs 35.9%).

GLP-1CardiovascularKidneyType 2 diabetesDrug comparisonsEli Lilly Novo Nordisk

PubMed23 Mar 2026·Diabetes, obesity & metabolism● 8/10iHigh impact

GLP-1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta-Analysis of RCTs.

Tirzepatide achieved 7.17-fold greater likelihood of ≥5% weight loss versus placebo in adults with type 2 diabetes, outperforming subcutaneous semaglutide (4.74-fold) and oral semaglutide (2.85-fold). Network meta-analysis of 127 RCTs, 58,976 participants across seven GLP-1 receptor agonists. This provides the first comprehensive head-to-head comparison showing tirzepatide's superior weight loss efficacy across both diabetes and non-diabetes populations. Higher nausea and vomiting rates occurred with tirzepatide versus semaglutide formulations.

GLP-1Weight lossType 2 diabetesDrug comparisonsEli Lilly Novo Nordisk

PubMed21 Mar 2026·Lancet (London, England)● 8/10iHigh impact

Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.

Orforglipron 12 mg and 36 mg achieved superior HbA1c reduction versus oral semaglutide 7 mg and 14 mg, with treatment differences ranging from -0.24% to -0.68%. Phase 3 RCT with 1,698 adults with type 2 diabetes inadequately controlled on metformin, 52-week duration, head-to-head comparison. This provides the first head-to-head data showing an oral non-peptide GLP-1 receptor agonist outperforming oral semaglutide in glycemic control. Higher gastrointestinal side effects and discontinuation rates with orforglipron (9-10% vs 4-5%) may limit uptake despite superior efficacy.

GLP-1Type 2 diabetesDrug comparisonsEli Lilly Novo Nordisk

FDA19 Mar 2026·Supplemental Approval — Efficacy● 6/10i

FDA Approves Wegovy (Semaglutide) — Supplemental Approval — Efficacy

FDA approved a supplemental efficacy application for Wegovy (semaglutide, Novo Nordisk) on March 19, 2026. This represents a label expansion for the already-approved obesity drug, adding new efficacy data or indication refinements to the existing NDA. Novo Nordisk continues to strengthen Wegovy's competitive position in the obesity market against Eli Lilly's Zepbound through additional clinical evidence.

GLP-1Weight lossNovo Nordisk Eli Lilly

FDA19 Mar 2026·FDA Press Release● 6/10i

FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide

FDA approved a higher dose of Wegovy (semaglutide 7.2 mg) for weight loss and long-term weight maintenance in adults on March 19, 2026. This represents a label expansion for the existing obesity indication, building on Wegovy's current 2.4 mg weekly injection. Novo Nordisk gains a potential differentiation tool in the competitive obesity market, where Eli Lilly's Zepbound already offers dual-mechanism action. The approval marks the fourth product under FDA's National Priority Voucher Program.

GLP-1Weight lossNovo Nordisk

ClinicalTrials13 Mar 2026·Phase 3● 5/10i

A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

A phase 3 trial is testing KAI-9531, a once-weekly subcutaneous injection, versus semaglutide and placebo for weight loss in 1,200 people with obesity without diabetes. The 76-week randomized, partially-blinded study targets completion in March 2028 with percent body weight change as the primary endpoint. Kailera is positioning KAI-9531 as a direct competitor to Wegovy in the crowded obesity market, attempting to differentiate through superior weight loss efficacy. This represents another entrant challenging Novo Nordisk's established position in obesity treatment.

GLP-1Weight lossKailera Novo Nordisk

ClinicalTrials12 Mar 2026·Phase 3● 7/10i

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 8)

Phase 3 trial (AMAZE 8) comparing Novo Nordisk's investigational NNC0487-0111 to semaglutide for weight loss in adults with overweight or obesity and type 2 diabetes. Targeting 1,000 participants with expected completion in December 2028, this head-to-head comparison uses body weight change as the primary endpoint. Novo Nordisk is testing a potential next-generation GLP-1 against its own approved semaglutide, suggesting confidence in superior weight loss efficacy. This positions NNC0487-0111 as a potential successor to Wegovy in the competitive obesity market.

GLP-1Weight lossType 2 diabetesDrug comparisonsNovo Nordisk

ClinicalTrials12 Mar 2026·Phase 3● 8/10iHigh impact

The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease

Phase 3 cardiovascular outcomes trial evaluating CagriSema (cagrilintide + semaglutide 2.4 mg/2.4 mg) versus placebo in people with established cardiovascular disease. 7,101 participants enrolled with up to 4.5 years follow-up, measuring time to first 3-point MACE (cardiovascular death, non-fatal MI, non-fatal stroke). Novo Nordisk is testing whether their dual amylin/GLP-1 combination can deliver cardiovascular benefits beyond current GLP-1 monotherapy in high-risk populations. This represents the first major cardiovascular outcomes trial for a dual incretin/amylin combination therapy.

GLP-1CardiovascularWeight lossNovo Nordisk

ClinicalTrials11 Mar 2026·Phase 3● 6/10i

Long-term Effects of Semaglutide on Diabetic Retinopathy in Subjects With Type 2 Diabetes

Phase 3 randomized controlled trial evaluating semaglutide versus placebo for diabetic retinopathy progression in adults with type 2 diabetes. The 5-year study targets 1,500 participants and measures 3-step Early Treatment Diabetic Retinopathy Study progression as primary endpoint. Novo Nordisk is testing whether their established GLP-1 can expand beyond diabetes and weight management into ophthalmology, potentially opening a new indication where no GLP-1 currently holds approval. This represents one of the longest-duration ophthalmology studies in the metabolic space.

GLP-1Type 2 diabetesNovo Nordisk

ClinicalTrials27 Feb 2026·Phase 3● 5/10i

A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Study Comparing the Efficacy and Safety of HRS9531 Injection Versus Semaglutide Injection in Subjects With Obesity

HRS9531, a weekly injectable from Chinese sponsor Fujian Shengdi, is being tested head-to-head against semaglutide in 572 adults with obesity. This 52-week, open-label phase 3 trial completed enrollment and measures percentage weight change as the primary endpoint. The study represents another Chinese GLP-1 biosimilar or follow-on entering direct competition with Novo Nordisk's established semaglutide franchise in obesity. This adds to multiple Chinese developers pursuing GLP-1 programs, potentially targeting domestic and emerging markets where branded pricing creates access gaps.

GLP-1Weight lossDrug comparisonsFujian Shengdi Pharmaceutical Co., Ltd.Novo Nordisk

ClinicalTrials25 Feb 2026·Phase 3● 6/10i

A Placebo-controlled Comparability Study to Compare Two Presentations of CagriSema in Participants With Overweight or Obesity

Phase 3 trial compares two presentation formats of CagriSema (cagrilintide plus semaglutide) delivered via different injection devices for weight loss in adults with overweight or obesity. The placebo-controlled study plans to enroll 1,400 participants with completion expected in late 2027. This device comparability study reflects Novo Nordisk's preparation for potential CagriSema approval, ensuring multiple delivery options for their dual hormone approach. The timing suggests Novo is advancing toward late-stage regulatory preparations for their next-generation weight management therapy.

GLP-1Weight lossNovo Nordisk

ClinicalTrials12 Jan 2026·Phase 3● 8/10iHigh impact

A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity

Phase 3 cardiovascular outcomes trial testing tirzepatide versus placebo in 15,374 adults with obesity, measuring time to first major adverse cardiovascular event (death, MI, stroke, coronary revascularization, or heart failure). The randomized, double-blind, placebo-controlled study completed enrollment with expected results in October 2027. This represents Eli Lilly's bid to establish tirzepatide's cardiovascular benefits in obesity, directly competing with Novo Nordisk's Wegovy which gained MACE indication approval in March 2024. The massive enrollment suggests Lilly is positioning for a broad obesity cardiovascular claim to differentiate from Novo's narrower obesity plus established CVD indication.

GLP-1Weight lossCardiovascularEli Lilly Novo Nordisk

ClinicalTrials12 Dec 2025·Phase 3● 8/10iHigh impact

Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c. (CagriSema s.c.) Once Weekly for Weight Management and Long-term Weight Maintenance in Participants With Obesity

Novo Nordisk is testing CagriSema (cagrilintide plus semaglutide combination) against placebo in 609 people with obesity across a 3-year phase 3 trial for weight management and long-term maintenance. The study includes a main phase followed by an extension where all participants receive active treatment at different doses. This represents Novo's dual-hormone strategy to extend beyond single GLP-1 therapy, competing directly with Eli Lilly's tirzepatide franchise in obesity. The 3-year duration targets the critical question of sustained weight loss that regulators and payers prioritize.

Weight lossGLP-1Novo Nordisk Eli Lilly

ClinicalTrials5 Nov 2025·Phase 3● 8/10iHigh impact

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)

ATTAIN-1 is testing orforglipron, Eli Lilly's oral small-molecule GLP-1 receptor agonist, versus placebo in 3,127 adults with obesity or overweight with weight-related comorbidities. This 72-week phase 3 trial with 2-year extension for people with prediabetes is placebo-controlled and has completed enrollment. Eli Lilly is building the clinical foundation for orforglipron in obesity, following its April 2026 FDA approval for type 2 diabetes where it differentiated from Novo Nordisk's oral semaglutide with no dosing restrictions. This represents Eli Lilly's entry into oral GLP-1 obesity treatment, directly challenging Novo Nordisk's pending high-dose oral semaglutide for obesity approved in January 2026.

GLP-1Weight lossEli Lilly Novo Nordisk

ClinicalTrials24 Aug 2025·Phase 3● 5/10i

A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Patients With Type 2 Diabetes

RAY1225, a GLP-1 receptor agonist from Guangdong Raynovent Biotech, is being tested head-to-head against semaglutide as add-on therapy to oral antidiabetic drugs in adults with type 2 diabetes. The open-label phase 3 trial targets 600 participants with expected completion in December 2026, measuring HbA1c reduction as the primary endpoint. This represents another Chinese biotech company attempting to challenge Novo Nordisk's semaglutide dominance in the established GLP-1 diabetes market. The direct comparator design suggests confidence in differentiation, though the open-label format may limit regulatory acceptance versus blinded superiority trials.

GLP-1Type 2 diabetesDrug comparisonsGuangdong Raynovent Biotech Novo Nordisk

ClinicalTrials12 Jun 2025·Phase 3● 5/10i

A Phase III,Multicenter,Randomized,Open-label,Parallel-controlled Study Comparing the Efficacy and Safety of HRS9531 With Semaglutide in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Metformin Monotherapy or in Combination With SGLT2 Inhibitors

HRS9531, a once-weekly GLP-1 agonist from Fujian Shengdi Pharmaceutical, is being tested head-to-head against semaglutide in adults with type 2 diabetes inadequately controlled on metformin with or without SGLT2 inhibitors. The phase 3 randomized open-label trial enrolled 884 people with 52-week follow-up, measuring HbA1c change as the primary endpoint. This represents another Chinese biosimilar challenge to Novo Nordisk's semaglutide franchise, following similar efforts from BrightGene and Raynovent in the competitive GLP-1 space. The trial completed enrollment and is expected to read out by September 2026.

GLP-1Type 2 diabetesDrug comparisonsFujian Shengdi Pharmaceutical Novo Nordisk

ClinicalTrials18 Apr 2025·Phase 3● 8/10iHigh impact

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)

TRIUMPH-1 is a Phase 3 master protocol testing retatrutide (Eli Lilly's triple agonist) in 2,300 people with obesity or overweight without type 2 diabetes, including subsets with knee osteoarthritis and obstructive sleep apnea. The 89-week double-blind, placebo-controlled trial with optional 24-week extension measures weight change, osteoarthritis pain scores, and sleep apnea severity. Eli Lilly is positioning retatrutide across multiple obesity-related conditions beyond weight management, directly competing with Novo Nordisk's Wegovy in the obesity market. This comprehensive approach targets three distinct indications within one protocol, reflecting Lilly's strategy to establish retatrutide as a multi-indication obesity therapy.

Weight lossCardiovascularEli Lilly Novo Nordisk

ClinicalTrials7 Feb 2025·Phase 3● 5/10i

A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of BGM0504 Versus Semaglutide Once Weekly As Add-on Therapy to Metformin And/or Sulfonylureas in Patients with Type 2 Diabetes

BGM0504, a once-weekly injection from BrightGene Bio-Medical, is being tested against semaglutide as add-on therapy to metformin and/or sulfonylureas in adults with type 2 diabetes. The open-label phase 3 trial enrolls 537 participants in China with expected completion in March 2026. This represents a direct challenge to Novo Nordisk's Ozempic franchise in the Chinese market from a domestic biosimilar competitor. The head-to-head design against branded semaglutide signals BrightGene's confidence in demonstrating non-inferiority for regulatory approval and market access positioning.

GLP-1Type 2 diabetesDrug comparisonsBrightGene Bio-Medical Technology Co., Ltd.Novo Nordisk

ClinicalTrials19 Aug 2024·Phase 3● 5/10i

A 26-Week,Randomised,Open-Label,Multicenter,Active-Controlled,Parallel-Design,Phase III Clinical Trial to Compare the Efficacy and Safety of Insulin Degludec/Liraglutide Injection With XULTOPHY® Once Daily Via Subcutaneous Injection in Chinese Subjects With Type 2 Diabetes

Phase 3 trial compares Chinese-manufactured insulin degludec/liraglutide combination to Novo Nordisk's Xultophy in adults with type 2 diabetes. Open-label study targets 510 participants over 26 weeks with HbA1c reduction as primary endpoint, expected completion October 2025. Tonghua Dongbao tests its biosimilar combination against the established Novo Nordisk product in the Chinese market. This represents China's push toward domestic alternatives in the GLP-1/insulin combination space.

GLP-1Type 2 diabetesDrug comparisonsTonghua Dongbao Pharmaceutical Co.,Ltd Novo Nordisk